PHP
EWTX icon

Parkman Healthcare Partners’s Edgewise Therapeutics EWTX Stock Holding History

Parkman Healthcare Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Sell
322,828
-104,862
-25% -$3.02M 1.05% 34
2025
Q4 		$10.6M Sell
427,690
-122,483
-22% -$2.46M 1.01% 36
2025
Q3 		$8.92M Sell
550,173
-97,158
-15% -$1.38M 0.93% 39
2025
Q2 		$8.49M Buy
647,331
+221,924
+52% +$3.2M 0.98% 35
2025
Q1 		$9.36M Buy
425,407
+44,234
+12% +$1.16M 1.11% 34
2024
Q4 		$10.2M Sell
381,173
-275,897
-42% -$8.78M 1.36% 28
2024
Q3 		$17.5M Buy
657,070
+82,553
+14% +$1.64M 2.24% 12
2024
Q2 		$10.3M Sell
574,517
-79,136
-12% -$1.38M 1.39% 26
2024
Q1 		$11.9M Buy
653,653
+2,028
+0.3% +$32.2K 1.46% 23
2023
Q4 		$7.13M Buy
651,625
+178,313
+38% +$1.25M 1% 33
2023
Q3 		$2.71M Buy
473,312
+19,065
+4% +$130K 0.5% 60
2023
Q2 		$3.52M Buy
454,247
+391,964
+629% +$3.31M 0.61% 53
2023
Q1 		$415K Buy
62,283
+9,387
+18% +$87K 0.09% 81
2022
Q4 		$473K Buy
52,896
+2,896
+6% +$27.1K 0.13% 78
2022
Q3 		$492K Buy
+50,000
New +$505K 0.14% 84

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Parkman Healthcare Partners's EWTX Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Edgewise Therapeutics (EWTX) stake by 25% in Q1 2026, selling an estimated $3.02M and leaving 322,828 shares worth $10.2M. The position accounts for 1.05% of the portfolio, ranked #34.

Parkman Healthcare Partners first reported a position in EWTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $17.5M in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Parkman Healthcare Partners held 322,828 shares of Edgewise Therapeutics worth $10.2M as of Q1 2026.
  • Parkman Healthcare Partners sold 104,862 Edgewise Therapeutics shares in Q1 2026, an estimated $3.02M.
  • Edgewise Therapeutics made up 1.05% of Parkman Healthcare Partners's portfolio in Q1 2026, its #34 holding.
  • Parkman Healthcare Partners first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Parkman Healthcare Partners's Edgewise Therapeutics position peaked at $17.5M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.